Antitrust

Former Texas Chief Justice Wallace B. Jefferson will helm the nation's top legal reform body, bringing a unique legacy to an era of democratic pressure.

An investor law firm is investigating IBM's $31 per share offer for Confluent, questioning if the price shortchanges shareholders of the data-streaming giant.

A former police officer's unique law firm is gaining global attention for defending clients at the perilous intersection of criminal and immigration law.

Travel giant Trip.com Group faces a major anti-monopoly investigation in China, sending its stock plummeting and signaling a new phase in the tech crackdown.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

A wellness company is calling out the supplement industry, claiming many popular shilajit gummies are ineffective, candy-like products. Here's what's real.

With new executive leadership, AI firm HealthLeap aims to accelerate its mission of improving patient outcomes and hospital finances nationwide.

A tech firm is leveraging sound waves to overcome key hurdles in brain-computer interfaces, paving the way for advanced rehabilitation and assistive care.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

The family of a motorcyclist killed by a Tesla on Autopilot files a wrongful death suit, citing a history of deceptive marketing and known system flaws.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

A Minnesota law firm's call for a state investigation into a fatal ICE shooting ignites a fierce debate on state vs. federal power and accountability.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

The Golden Globes partners with prediction market Polymarket in a bold bid for relevance, but the high-stakes deal brings new scrutiny and ethical questions.

Crypto exchange HTX reveals 39% growth in its 2025 report, but the real story is its strategic pivot to tech, compliance, and long-term value.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

Two of New England’s top litigation firms are joining forces, creating a regional giant with expanded resources and deep trial expertise for injury victims.

The SEC proposes a landmark update to its 'small entity' definition, a move poised to slash red tape for thousands of firms and foster market competition.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.